An unmet need exists for effective glucocorticoid-sparing agents for the treatment of giant cell arteritis (GCA). Tocilizumab, the first intervention to demonstrate substantial therapeutic benefits for patients with newly diagnosed or relapsing GCA, is changing the landscape of treatment and ushering in a new era of biologic therapy.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Mahr, A. D. et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 56, 2789–2797 (2007).
Stone, J. H. et al. Trial of tocilizumab in giant-cell arteritis. N. Engl. J. Med. 377, 317–328 (2017).
Villiger, P. M. et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase II, randomised, double-blind, placebo-controlled trial. Lancet 387, 1921–1927 (2016).
Koster, M. J., Matteson, E. L. & Warrington, K. J. Recent advances in the clinical management of giant cell arteritis and Takayasu arteritis. Curr. Opin. Rheumatol 28, 211–217 (2016).
Tuckwell, K. et al. Newly diagnosed versus relapsing giant cell arteritis: baseline data from the GiACTA trial. Semin. Arthritis Rheum. 46, 657–664 (2017).
Unizony, S. et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res. (Hoboken) 64, 1720–1729 (2012).
Garcia-Martinez, A. et al. Prospective long term follow-up of a cohort of patients with giant cell arteritis screened for aortic structural damage (aneurysm or dilatation). Ann. Rheum. Dis. 73, 1826–1832 (2014).
Maleszewski, J. J. et al. Clinical and pathological evolution of giant cell arteritis: a prospective study of follow-up temporal artery biopsies in 40 treated patients. Mod. Pathol. 30, 788–796 (2017).
Weyand, C. M. & Goronzy, J. J. Immune mechanisms in medium and large-vessel vasculitis. Nat. Rev. Rheumatol 9, 731–740 (2013).
Langford, C. A. et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol. 69, 837–845 (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Koster, M., Warrington, K. Tocilizumab — a new frontier for GCA therapy. Nat Rev Rheumatol 13, 700–701 (2017). https://doi.org/10.1038/nrrheum.2017.150
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2017.150